US phase I trial of the Amplatzer® Membranous VSD Occluder
Claire Braybrook
This article has no abstract so we have provided the first paragraph of the full text.
Perimembranous ventricular septal defects (VSDs) involving the membranous septum and the adjoining muscular septum are the most common form of congenital heart defect. Traditional surgical repair techniques are associated with an increased risk of complications such as complete heart block, arrhythmias, wound infection and neurologic sequelae. The Amplatzer® Membranous VSD Occluder (AGA Medical Corporation, Golden Valley, MN) has been specifically designed to repair perimembranous VSDs with minimal incursion on the aortic valve. Several small trials have reported successful defect closure using this device in the past few years.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
